CorMedix has consolidated the preliminary Q4 numbers — with a new company update, the wedge formation could soon break upward!
Reading Time: 1 minute
CorMedix is a biotechnology company offering DefenCath, an antimicrobial solution for the prevention of catheter-related bloodstream infections (CRBSI), which are common in dialysis patients and can lead to severe complications such as sepsis. Initially launched in hospitals, the product was also approved for use in outpatient dialysis centers in the summer of 2024. In addition to the dialysis sector, CorMedix is continuously expanding its product pipeline. The company plans to utilize DefenCath in Total Parenteral Nutrition (TPN) – a method...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
